AUG 09 2004 PATENT & TRADEMARK OFFICE

IFW

Attorney Docket No. KNP017 (15871/124)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re App	:	John Brekke and John Gubbe	:	Art Unit 1614
Serial No.	:	10/690,972	:	Confirmation No. 4698
Filed	:	October 21, 2003		
For	:	Device and Methods for Sequential, Regional Delivery of Multiple Cytotoxic Agents and Directed Assembly of Wound Repair Tissues		

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE U.S. POSTAL SERVICE AS FIRST CLASS MAIL WITH SUFFICIENT POSTAGE AND IS ADDRESSED TO THE COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON AUGUST 5, 2004 (37 C.F.R. 1.8a).

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER RULE 1.56

In continuation of the Information Disclosure Statement Under Rule 1.56 mailed on July 30, 2004, applicants herein make available to the Patent and Trademark Office a copy of Form PTO-1449 listing the enclosed references. This Information Disclosure Statement is being filed in accordance with the 37 CFR 1.97(b)(3) before the mailing date of a first Office Action on the merits.

This listing should not be construed as representation that a search has been made or that no better art exists. No inference should be made that the documents are in fact material merely because they are referenced herein. Further, by this listing, the applicant is not making any admission regarding the relative dates of the invention and listed disclosures.

The Examiner is requested to consider carefully the complete text of these documents in connection with the examination of the above-identified application in accordance with 37 CFR 1.104(a). It is requested that the documents listed on the attached Form PTO-1449 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. 1302.12), and that the Examiner initial and return a copy of the form to evidence consideration of the documents.

Dated: August 5, 2004.

Respectfully submitted,

John Brekke and John Gubbe

Alan D. Kamrath
NIKOLAI & MERSEREAU, P.A.
Attorney for Applicants
Registration No. 28,227
900 Second Avenue South
Suite 820 International Centre
Minneapolis, MN 55402
Telephone: (612) 339-7461

OIPE
AUG 0 9 2004
PATENT & TRADEMARK OFFICE

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Docket Number **KNP017 (15871/124)**	Application Number **10/690,972**
	Applicant **John Brekke and John Gubbe**	
	Filing Date **October 21, 2003**	Group Art Unit **1614**

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

		Luo Y., Bernshaw, N. J., Lu, Z.-R., Kopecek, J., and Prestwich, G. D.: Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates, Pharamaceutical Res., 19(4): 396-402, 2002
		Dosio, F., Brusa, P., Crosasso, P., Arpicco, S., Cattel, L.: Preparation, characterization and properties *in vitro* and *in vivo* of a paclitaxel - albumin conjugate. J. Cont Rel, 47: 293-304, 1997.
		Brekke, J.H.: A rationale for delivery of osteoinductive proteins. Tissue Eng. 2(2): 97-114, 1996.
		Memorial Sloan-Kettering Cancer Center http://www.mskcc.org/mskcc/html/1879.cfm (2 pages).
		Reuters Business Insight Healthcare, Therapeutic Report Series: The Cancer Outlook to 2007, pages 1-210, 2002.

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.